| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/20/2007 | CA2218499C Chemokine binding protein and methods of use therefor |
| 02/20/2007 | CA2128044C Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor |
| 02/15/2007 | WO2007019549A2 Composition and method for use in cartilage affecting conditions |
| 02/15/2007 | WO2007018546A1 Modulation of cell fates and activities by phthalazinediones |
| 02/15/2007 | WO2007018320A1 Agent for prevention of graft loss, and screening method for the agent |
| 02/15/2007 | WO2007018316A1 Prophylactic/therapeutic agent for cancer |
| 02/15/2007 | WO2007018309A1 Method for evaluating compound using molecule on the rb pathway as index and molecular diagnostic method |
| 02/15/2007 | WO2007018143A1 Use of gene which varies in amount of expression during the course of transition from precancer to cancer |
| 02/15/2007 | WO2007017139A1 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| 02/15/2007 | WO2007017058A1 Therapeutic combination comprising a nmda receptors blocker and a narcotic analgesic substance |
| 02/15/2007 | WO2007016955A1 Alcohol metabolism moderating composition |
| 02/15/2007 | WO2007016954A1 Composition for reducing drug or alcohol induced breast cancer risk |
| 02/15/2007 | WO2007016953A1 Composition for reducing alcohol induced liver cancer risk |
| 02/15/2007 | WO2007016952A1 Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer |
| 02/15/2007 | WO2007016951A1 Composition for reducing the risc of alcohol induced pancreatic cancer |
| 02/15/2007 | WO2007016950A1 Composition for reducing the risk of alcohol induced neurodegenerative disease |
| 02/15/2007 | WO2007016949A1 Composition for reducing the risc of alcohol induced neuropathy |
| 02/15/2007 | WO2006135693A3 Direct compression formulation of dpp-iv inhibitors and glitazones, and process |
| 02/15/2007 | WO2006107944A3 Improved method and apparatus for treating bacterial infections in devices |
| 02/15/2007 | WO2006099095A3 Ribosome inhibitors as inhibitors of tyrosyl-dna-phosphodiesterase |
| 02/15/2007 | WO2005107810A3 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| 02/15/2007 | US20070039064 Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse |
| 02/15/2007 | US20070039063 Trangenic diploid cell comprising mutation in kinase allele for use in screening modulator for treatment of anxiety, addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures and epilepsy |
| 02/15/2007 | US20070039062 Goodpasture's syndrome model mouse |
| 02/15/2007 | US20070037879 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 02/15/2007 | US20070037878 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 02/15/2007 | US20070037848 Treatment of neurological conditions |
| 02/15/2007 | US20070037835 Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid |
| 02/15/2007 | US20070037803 Benzimidazole derivatives |
| 02/15/2007 | US20070037772 Pyrazolidinol compounds |
| 02/15/2007 | US20070037750 Exendin agonist composed of a peptide in which at least one amino acid residue is acylated with a dicarboxylic acid; the amino acid residues are an internal lysine residue, an N-terminal amino acid residue, and/or a C-terminal amino acid residue; treatment of glucagonoma |
| 02/15/2007 | US20070037740 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| 02/15/2007 | US20070037735 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 02/15/2007 | US20070037218 Human gene critical to fertility |
| 02/15/2007 | US20070037145 drug screening; for carcinomas, especially lymphoma carcinomas |
| 02/15/2007 | US20070037136 Harvesting, separating, culturing and exposing tissue to antiproliferative agents, monitoring variation in tissue propagation; immunotherapeutics; wound healing agents |
| 02/15/2007 | US20070036876 Relieving pain at a body site by administering a dosage of capsaicinoid at the painful site without eliciting an effect outside the discrete location; local anesthetic effect; targeted therapy |
| 02/15/2007 | US20070036860 Treatment of allergic conditions |
| 02/15/2007 | US20070036854 Therapeutic applications of pro-apoptotic benzodiazepines |
| 02/15/2007 | US20070036790 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036784 Medicament for the protection against thrombotic diseases |
| 02/15/2007 | US20070036768 Systems and methods for treating patients with processed lipoaspirate cells |
| 02/15/2007 | US20070036755 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036754 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036753 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036751 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 02/15/2007 | DE112005000708T5 Ionen bindende Zusammensetzung Ion scavenging composition |
| 02/15/2007 | DE102005036656A1 Pharmaceutical composition containing IKK-beta inhibitor and agent for treating inflammation or tumor of the skin, useful for topical treatment of e.g. inflamed skin and tumors of the eye |
| 02/15/2007 | CA2618657A1 Method for evaluating compound using molecule on the rb pathway as index and molecular diagnostic method |
| 02/15/2007 | CA2618542A1 Prophylactic/therapeutic agent for cancer |
| 02/15/2007 | CA2618256A1 Modulation of cell fates and activities by phthalazinediones |
| 02/15/2007 | CA2618093A1 Composition and method for use in cartilage affecting conditions |
| 02/15/2007 | CA2616659A1 Therapeutic combination comprising a nmda receptors blocker and a narcotic analgesic substance |
| 02/15/2007 | CA2611389A1 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| 02/15/2007 | CA2607219A1 Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity |
| 02/14/2007 | EP1752164A1 Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic |
| 02/14/2007 | EP1752160A2 Epitope sequences |
| 02/14/2007 | EP1752152A1 Agent for visualizing transparent tissue |
| 02/14/2007 | EP1752146A1 Therapeutic agent for diabetes |
| 02/14/2007 | EP1752145A1 Therapeutic agent for hyperlipemia and therapeutic agent for diabetes |
| 02/14/2007 | EP1752143A1 Novel uses for drugs targeting glutamine synthetase |
| 02/14/2007 | EP1751612A2 Methods and compositions for the treatment of uveitis |
| 02/14/2007 | EP1750862A2 Pharmaceutical composition containing irbesartan |
| 02/14/2007 | EP1750768A2 Use of targeted oxidative therapeutic formulation in bone regeneration |
| 02/14/2007 | EP1750766A2 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| 02/14/2007 | EP1750765A2 Antimycobacterial pharmaceutical composition comprising an antitubercular drug |
| 02/14/2007 | EP1750726A2 Spermicidal and virucidal properties of various forms of sophorolipids |
| 02/14/2007 | EP1750712A2 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| 02/14/2007 | EP1750709A2 Method for the treatment of back pain |
| 02/14/2007 | EP1750708A1 Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors |
| 02/14/2007 | EP1750707A1 Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and toll-like receptor 4 agonist |
| 02/14/2007 | EP1750703A1 Method for reducing gastrointestinal toxicity due to the administration of tegafur |
| 02/14/2007 | EP1750697A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 02/14/2007 | EP1750690A1 Use of targeted oxidative therapeutic formulation in treatment of cancer |
| 02/14/2007 | EP1750688A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 02/14/2007 | EP1750682A2 Nutritional formulations |
| 02/14/2007 | EP1750667A2 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 02/14/2007 | EP1750655A1 Personal care compositions and methods for regulating mammalian hair growth and skin condition |
| 02/14/2007 | EP1750527A1 Compositions and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| 02/14/2007 | EP1539796B1 Anti-inflammatory or anti-allergic androstane complexes |
| 02/14/2007 | EP1536777B1 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 02/14/2007 | EP1444220B1 Compounds and method for the treatment of overactive bladder |
| 02/14/2007 | EP1414409B1 Stabilized oral suspension formulation |
| 02/14/2007 | EP1392355B1 Use of proteasome inhibitors to treat dry eye disorders |
| 02/14/2007 | EP1345928B1 Pyrazole compounds useful as protein kinase inhibitors |
| 02/14/2007 | EP1328277B1 Bisphosphonic compounds for strengthening of cortical bone |
| 02/14/2007 | EP1267857B1 In vitro use of astaxanthin for pretreatment of cells prior to UV-exposure to inhibit the activation of NF-kB |
| 02/14/2007 | EP1260590B1 Method of screening substance specifically inhibiting non-mevalonate pathway |
| 02/14/2007 | EP1259234B9 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 02/14/2007 | EP1246639B1 Glp-2 formulations |
| 02/14/2007 | EP1200458B1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 02/14/2007 | EP1143976B9 Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
| 02/14/2007 | EP1140147B1 hCG THERAPY FOR THE TREATMENT OF METASTATIC BREAST CANCER |
| 02/14/2007 | EP1128813B1 An inhalation system |
| 02/14/2007 | EP1126836B1 Benzamide potassium channel inhibitors |
| 02/14/2007 | EP1124959B1 Cell surface molecule-induced macrophage activation |
| 02/14/2007 | EP1083929B1 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 02/14/2007 | EP0999845B1 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 02/14/2007 | CN1914168A Peptidyl arginine deiminase type IV inhibitor |
| 02/14/2007 | CN1914151A Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |